Phase I/II study about toxicity and efficacy of an anti-CD30/CD16 bispecific monoclonal antibody in patients with Hodgkin's disease in >=2. relapse - Forschungsportal der Justus-Liebig-Universität Gießen:

Meeting Abstract

Phase I/II study about toxicity and efficacy of an anti-CD30/CD16 bispecific monoclonal antibody in patients with Hodgkin's disease in >=2. relapse

Autorenliste: Hartmann, F; Renner, C; Jung, W; Deisting, C; Trumper, L; Pfreundschuh, M

Jahr der Veröffentlichung: 1995

Seiten: 3243-3243

Zeitschrift: Blood

Bandnummer: 86

Heftnummer: 10, Suppl. 1

ISSN: 0006-4971

Konferenz: 37th Annual Meeting of the American Society of Hematology

Verlag: American Society of Hematology (ASH Publications)

Zitierstile

Harvard-Zitierstil: Hartmann, F., Renner, C., Jung, W., Deisting, C., Trumper, L. and Pfreundschuh, M. (1995) Phase I/II study about toxicity and efficacy of an anti-CD30/CD16 bispecific monoclonal antibody in patients with Hodgkin's disease in >=2. relapse, Blood, 86(10, Suppl. 1), p. 3243

APA-Zitierstil: Hartmann, F., Renner, C., Jung, W., Deisting, C., Trumper, L., & Pfreundschuh, M. (1995). Phase I/II study about toxicity and efficacy of an anti-CD30/CD16 bispecific monoclonal antibody in patients with Hodgkin's disease in >=2. relapse. Blood. 86(10, Suppl. 1), 3243.